Literature DB >> 11696721

Familial bladder cancer in the National Swedish Family Cancer Database.

K Plna1, K Hemminki.   

Abstract

PURPOSE: We analyzed the risk of bladder cancer in offspring according to parental and sibling cancer using the national Swedish Family Cancer Database.
MATERIALS AND METHODS: Cancer data were obtained from the Swedish Cancer Registry for 1958 to 1996, including 2,105 cases of bladder cancer in offspring. The standardized incidence ratio was used to measure cancer risk in offspring according to familial cancer status.
RESULTS: The incidence ratio of bladder cancer increased in Sweden from 1958 to 1996 and it was 3 to 4-fold higher in males than in females. We identified 65 families in which the parents and offspring had bladder cancer with a familial risk of 1.35 (95% confidence interval [CI] 0.97 to 1.79) in sons and 2.29 (95% CI 1.46 to 3.29) in daughters. Discordant cancer sites associated with bladder cancer in the 2 generations were the kidney and thyroid with a standardized incidence ratio of 1.58 (95% CI 1.18 to 2.05) and 1.89 (95% CI 1.00 to 3.05), respectively. Sibling risk was higher compared with offspring risk with a standardized incidence ratio of 2.96 (95% CI 1.41 to 5.08) and in males there was a statistically significant ratio of sibling-to-offspring risk of 2.66 (95% CI 1.29 to 5.45). Patient age at onset modified the familial risk. The highest familial risk of 7.26 (95% CI 2.61 to 14.24) was observed in the brothers of bladder cancer probands diagnosed before age 45 years.
CONCLUSIONS: The relatively high ratio of sibling-to-offspring risk as well as observed gender specific effects in bladder cancer may reflect an X linked susceptibility gene.

Entities:  

Mesh:

Year:  2001        PMID: 11696721

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  17 in total

1.  X-linked tumor suppressors: perplexing inheritance, a unique therapeutic opportunity.

Authors:  Yang Liu; Lizhong Wang; Pan Zheng
Journal:  Trends Genet       Date:  2010-04-29       Impact factor: 11.639

Review 2.  Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.

Authors:  Andrew Rh Shepherd; Emily Shepherd; Nicholas R Brook
Journal:  Cochrane Database Syst Rev       Date:  2017-03-08

3.  Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance.

Authors:  Sigurdur Y Kristinsson; Lynn R Goldin; Magnus Björkholm; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-06-22       Impact factor: 9.941

4.  Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study.

Authors:  Christopher Martin; Claire L Leiser; Brock O'Neil; Sumati Gupta; William T Lowrance; Wendy Kohlmann; Samantha Greenberg; Piyush Pathak; Ken R Smith; Heidi A Hanson
Journal:  J Natl Cancer Inst       Date:  2018-05-01       Impact factor: 13.506

Review 5.  Familial and genetic risk of transitional cell carcinoma of the urinary tract.

Authors:  Christine M Mueller; Neil Caporaso; Mark H Greene
Journal:  Urol Oncol       Date:  2008-06-18       Impact factor: 3.498

6.  Contribution of the Defective BRCA1, BRCA2 and CHEK2 Genes to the Familial Aggregation of Breast Cancer: a Simulation Study Based on the Swedish Family-Cancer Database.

Authors:  Justo Lorenzo Bermejo; Alfonso García Pérez; Kari Hemminki
Journal:  Hered Cancer Clin Pract       Date:  2004-11-15       Impact factor: 2.857

7.  Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden.

Authors:  Sigurdur Y Kristinsson; Magnus Björkholm; Lynn R Goldin; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal:  Int J Cancer       Date:  2009-11-01       Impact factor: 7.396

8.  Cancer Susceptibility Mutations in Patients With Urothelial Malignancies.

Authors:  Maria I Carlo; Vignesh Ravichandran; Preethi Srinavasan; Chaitanya Bandlamudi; Yelena Kemel; Ozge Ceyhan-Birsoy; Semanti Mukherjee; Diana Mandelker; Joshua Chaim; Andrea Knezevic; Satshil Rana; Zarina Fnu; Kelsey Breen; Angela G Arnold; Aliya Khurram; Kaitlyn Tkachuk; Catharine K Cipolla; Ashley Regazzi; A Ari Hakimi; Hikmat Al-Ahmadie; Guido Dalbagni; Karen A Cadoo; Michael F Walsh; Min-Yuen Teo; Samuel A Funt; Jonathan A Coleman; Bernard H Bochner; Gopa Iyer; David B Solit; Zsofia K Stadler; Liying Zhang; Jonathan E Rosenberg; Barry S Taylor; Mark E Robson; Michael F Berger; Joseph Vijai; Dean F Bajorin; Kenneth Offit
Journal:  J Clin Oncol       Date:  2019-12-03       Impact factor: 44.544

9.  Familial risk of urological cancers: data for clinical counseling.

Authors:  Kari Hemminki; Xinjun Li; Kamila Czene
Journal:  World J Urol       Date:  2003-11-13       Impact factor: 4.226

10.  Survival in bladder and renal cell cancers is familial.

Authors:  Jianguang Ji; Asta Försti; Jan Sundquist; Per Lenner; Kari Hemminki
Journal:  J Am Soc Nephrol       Date:  2008-02-06       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.